<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Merck &amp; Company Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/merck-co-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Begins Mid-Stage Trial</title>
		<link>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916</link>
		<comments>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916#comments</comments>
		<pubDate>Wed, 23 Sep 2009 19:42:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALTU]]></category>
		<category><![CDATA[Altus Pharmaceuticals Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15916</guid>
		<description><![CDATA[Yesterday, BioMarin Pharmaceutical Inc. (BMRN) said it started a mid-stage study of PEG-PAL for the treatment of phenylketonuria (PKU). The company expects initial results from the study in mid-2010. It is co-developing the candidate with Merck Serono (MRK). The primary objective of the open-label, multi-center study, to be conducted in up to 35 patients, is to evaluate the effect of PEG-PAL on blood phenylalanine (Phe) concentrations in PKU patients. The secondary objectives are to evaluate its safety and tolerability, immune response and steady state pharmacokinetics of subcutaneous injections of multiple dose levels. BioMarin, which competes with companies such as Enzon Pharmaceuticals Inc. (ENZN), Shire Plc (SHPGY) and Altus Pharmaceuticals Inc. (ALTU), already has Kuvan in the market for treating PKU. The primary difference between PEG-PAL and Kuvan is the mode ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Seeks European Union Approval of its Schering-Plough Purchase</title>
		<link>http://www.stockbloghub.com/2009/09/23/mrk-merck-seeks-european-union-approval-of-its-schering-plough-purchase/15910</link>
		<comments>http://www.stockbloghub.com/2009/09/23/mrk-merck-seeks-european-union-approval-of-its-schering-plough-purchase/15910#comments</comments>
		<pubDate>Wed, 23 Sep 2009 19:25:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15910</guid>
		<description><![CDATA[Yesterday, Merck &#38; Co. (MRK) announced that it is seeking approval from the European Union (EU) for its $41.1 billion acquisition of Schering-Plough Corp. (SGP). The regulatory authorities in the EU are expected to pass a verdict on the matter by Oct. 23. Merck filed for approval of the merger in the EU after the completion of the sale of its 50% interest in animal health company Merial Limited (Merial) to Sanofi-Aventis (SNY) for a cash consideration of $4 billion ( US ). As a reminder, Merial was founded in 1997. It was a 50/50 joint venture between Merck and Sanofi-Aventis and is now a wholly owned subsidiary of the latter. In 2008, Merial was ranked third in the animal health market, with a market share estimated at 13.8% and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/mrk-merck-seeks-european-union-approval-of-its-schering-plough-purchase/15910/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Drug Gets FDA OK</title>
		<link>http://www.stockbloghub.com/2009/09/18/nvs-novartis-drug-gets-fda-ok/15644</link>
		<comments>http://www.stockbloghub.com/2009/09/18/nvs-novartis-drug-gets-fda-ok/15644#comments</comments>
		<pubDate>Sat, 19 Sep 2009 00:50:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15644</guid>
		<description><![CDATA[The US Food and Drug Administration recently approved Novartis’ (NVS) Valturna for high blood pressure. The drug is a single-pill combination of Diovan (valsartan), an angiotensin receptor blocker, and Tekturna (aliskiren), the only approved direct renin inhibitor. We believe the approval is quite significant as Diovan, one of Novartis’ top-selling drugs with global sales of $5.7 billion in 2008 is losing patent protection in most European Union countries in 2011 and in the U.S. in 2012. Competition is likely to intensify shortly as Merck’s (MRK) Cozaar (2008 sales of $3.5 billion) will lose exclusivity in the U.S. in 2010, bringing in low-priced generics. The approval was based on a randomized, double-blind, placebo-controlled clinical trial on 1800 patients. The trial studied the impact of valsartan (160 mg and 320 mg) and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/nvs-novartis-drug-gets-fda-ok/15644/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck&#8217;s Isentress Wins Approval from the Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2009/09/18/mrk-mercks-isentress-wins-approval-from-the-food-and-drug-administration/15560</link>
		<comments>http://www.stockbloghub.com/2009/09/18/mrk-mercks-isentress-wins-approval-from-the-food-and-drug-administration/15560#comments</comments>
		<pubDate>Fri, 18 Sep 2009 17:03:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15560</guid>
		<description><![CDATA[The European Union (EU) recently expanded the approval of Merck’s (MRK) Isentress (raltegravir) for the first line treatment of HIV patients. Earlier, it was approved for patients who had not responded to other treatment options. In the US, following a recent Food and Drug Administration (FDA) approval, Isentress can be used in combination therapy for previously untreated patients as well. Isentress recorded worldwide sales of $172 million for the second quarter of 2009, an increase of 123% compared with the year-ago period. We believe the recent FDA and EU approval (for previously untreated patients) could increase the number of targeted patients considerably, leading to a significant rise in sales. We expect the drug to record more than $1 billion in revenues by 2011. Recently, at the 49th Interscience Conference on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/18/mrk-mercks-isentress-wins-approval-from-the-food-and-drug-administration/15560/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Good News for Dynavax Technologies</title>
		<link>http://www.stockbloghub.com/2009/09/11/mrk-good-news-for-dynavax-technologies/14966</link>
		<comments>http://www.stockbloghub.com/2009/09/11/mrk-good-news-for-dynavax-technologies/14966#comments</comments>
		<pubDate>Fri, 11 Sep 2009 23:24:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14966</guid>
		<description><![CDATA[Yesterday, Dynavax Technologies Corp. (DVAX) announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its late-stage hepatitis B vaccine (HBV) Heplisav which is being developed for patients suffering from chronic kidney disease. As a reminder, Heplisav was on clinical hold in the U.S since Mar 17, 2008 following the report of the severe adverse event (SAE) of Wegener&#8217;s granulomatosis. The SAE was reported in the phase III study in healthy adults conducted outside the U.S. Wegener&#8217;s granulomatosis is an uncommon disease which results in the inflammation of blood vessels .The vaccine is being studied for both healthy adults and patients with end-stage renal disease. Consequent to the regulatory issues, the partnership with Merck &#38; Co. Inc. (MRK) for Heplisav ended on December 19, 2008. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/mrk-good-news-for-dynavax-technologies/14966/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Amylin Pharmaceuticals Collaborates with Biocon</title>
		<link>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973</link>
		<comments>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973#comments</comments>
		<pubDate>Fri, 11 Sep 2009 23:16:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14973</guid>
		<description><![CDATA[Yesterday, Amylin Pharmaceuticals, Inc. (AMLN) entered into an exclusive agreement with Indian biotech company Biocon Limited for the development, commercialization and manufacture of a novel peptide therapeutic for the potential treatment of diabetes. This agreement should ensure the optimum utilization of the synergistic capabilities of both the companies. Both companies have a strong focus on the development of treatments for diabetes. While Amylin&#8217;s &#8220;phybrid&#8221; technology will be used for the development of the candidate, Biocon will use its know-how in recombinant microbial expression to manufacture the compound. A phybrid is a peptide hybrid molecule that combines the pharmacological effects of two peptide hormones into a single molecular entity. As per the terms of the agreement, development costs will be shared by the companies. Other details were not provided. The identification ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/amln-amylin-amylin-pharmaceuticals-collaborates-with-biocon/14973/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Updates Migraine Drug Status</title>
		<link>http://www.stockbloghub.com/2009/09/11/mrk-merck-updates-migraine-drug-status/14982</link>
		<comments>http://www.stockbloghub.com/2009/09/11/mrk-merck-updates-migraine-drug-status/14982#comments</comments>
		<pubDate>Fri, 11 Sep 2009 23:04:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14982</guid>
		<description><![CDATA[Yesterday, Merck (MRK) updated the status of two of its pipeline candidates, both used to treat migraine. While the company abandoned MK-3207, it will continue to develop telcagepant (MK-0974). Although MK-3207 was found to be effective, it caused liver abnormalities in some patients on discontinuing the drug. Due to this, Merck has decided to abandon any further studies of the drug. The phase III trial conducted by Merck for telcagepant found it to be more effective than placebo for acute treatment of multiple migraine attacks. In another study, the safety of the product was compared to another migraine drug of Merck, Maxalt (rizatriptan). The company presented data from both trials at the International Headache Congress and plans to initiate discussions regarding the next steps with the US Food and Drug ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/mrk-merck-updates-migraine-drug-status/14982/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) More Indications for Merck Drug</title>
		<link>http://www.stockbloghub.com/2009/09/10/mrk-more-indications-for-merck-drug/14910</link>
		<comments>http://www.stockbloghub.com/2009/09/10/mrk-more-indications-for-merck-drug/14910#comments</comments>
		<pubDate>Fri, 11 Sep 2009 02:13:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14910</guid>
		<description><![CDATA[Yesterday, an advisory panel of the US Food and Drug Administration (FDA) recommended the use of Merck’s (MRK) Gardasil vaccine in males 9 to 26 years of age to prevent genital warts. Originally, Gardasil was approved by the FDA in June 2006, as the first vaccine for cervical cancer, caused by human papillomavirus (HPV) for females 9 to 26 years of age. The panel voted 7-1 in favor of the vaccine’s safety and 7-0 (with one abstention) regarding its effectiveness. Although the FDA is not required to follow the panel’s recommendation, it generally does so. The final decision from the agency is expected by year end. Apart from the favorable recommendation, the panel members have expressed their concern about the lack of long-term data, which would have showed the timeframe ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/10/mrk-more-indications-for-merck-drug/14910/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline Moves Ahead With Cervarix</title>
		<link>http://www.stockbloghub.com/2009/09/10/gsk-glaxosmithkline-moves-ahead-with-cervarix/14895</link>
		<comments>http://www.stockbloghub.com/2009/09/10/gsk-glaxosmithkline-moves-ahead-with-cervarix/14895#comments</comments>
		<pubDate>Fri, 11 Sep 2009 02:11:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14895</guid>
		<description><![CDATA[Yesterday, GlaxoSmithKline (GSK) received a favorable recommendation from the US Food and Drug Administration&#8217;s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) for its cervical cancer vaccine, Cervarix. While the advisory committee voted 12-1 in favor of the efficacy of the vaccine, its safety profile got 11-1 in support from the panel. While the FDA is not bound by the advisory committee’s recommendation, it generally follows the suggestion. Cervarix was found to be highly effective and was well tolerated in the prevention of cervical pre-cancers and cervical cancer related to human papillomavirus (HPV) types 16 and 18, in girls and young women. Types 16 and 18 are the two most common virus types known to cause cervical cancer. The vaccine is currently approved in nearly 100 countries around the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/10/gsk-glaxosmithkline-moves-ahead-with-cervarix/14895/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) FDA Panel to Decide on HPV Vaccines</title>
		<link>http://www.stockbloghub.com/2009/09/09/mrk-fda-panel-to-decide-on-hpv-vaccines/14702</link>
		<comments>http://www.stockbloghub.com/2009/09/09/mrk-fda-panel-to-decide-on-hpv-vaccines/14702#comments</comments>
		<pubDate>Wed, 09 Sep 2009 22:15:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14702</guid>
		<description><![CDATA[We await the outcome of the US Food and Drug Administration’s (FDA) advisory panel meeting scheduled for today that will decide on various aspects of human papillomavirus (HPV) vaccines. Primarily there are two vaccines available for the prevention of cervical cancer in women &#8212; Merck’s (MRK) Gardasil and GlaxoSmithKline’s (GSK) Cervarix. Both vaccines are given in a series of three shots over a six-month period. Although Cervarix is approved in several countries, it has yet to gain FDA approval. In June 2006, the FDA approved the first cervical cancer vaccine, Gardasil (which targets four HPV strains: HPV 6, HPV 11, HPV 16 and HPV 18) for females 9 to 26 years of age. The FDA panel will decide on the approval of Cervarix (targets two HPV strains, HPV 16 and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/mrk-fda-panel-to-decide-on-hpv-vaccines/14702/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRTX) Cornerstone Therapeutics Wins Factive Rights</title>
		<link>http://www.stockbloghub.com/2009/09/08/crtx-cornerstone-therapeutics-wins-factive-rights/14642</link>
		<comments>http://www.stockbloghub.com/2009/09/08/crtx-cornerstone-therapeutics-wins-factive-rights/14642#comments</comments>
		<pubDate>Wed, 09 Sep 2009 00:04:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Cornerstone Therapeutics Inc]]></category>
		<category><![CDATA[CRTX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14642</guid>
		<description><![CDATA[Last week, Cornerstone Therapeutics Inc. (CRTX) announced the receipt of approval from the United States Bankruptcy Court for Massachusetts district regarding the acquisition of Factive&#8217;s (gemifloxacin mesylate) commercial rights  in North America and some European countries from Oscient Pharmaceuticals Corp., which filed for Chapter 11 bankruptcy protection in July. The transaction is worth $5 million in cash. Additionally, it includes an amount for purchased inventory, quarterly royalty payments based on adjusted net sales for a period of five years, and the assumption of certain liabilities. Factive, which belongs to the fluoroquinolone class of antibiotics, is indicated for the treatment of community-acquired pneumonia of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis (ABECB).  It was launched in the U.S. in September 2004 and is the only fluoroquinolone approved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/08/crtx-cornerstone-therapeutics-wins-factive-rights/14642/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) Good News for AstraZeneca on Crestor, its Cholesterol-Lowering Drug</title>
		<link>http://www.stockbloghub.com/2009/09/01/azn-good-news-for-astrazeneca-on-crestor-its-cholesterol-lowering-drug/14095</link>
		<comments>http://www.stockbloghub.com/2009/09/01/azn-good-news-for-astrazeneca-on-crestor-its-cholesterol-lowering-drug/14095#comments</comments>
		<pubDate>Tue, 01 Sep 2009 21:39:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Emeritus Corp.]]></category>
		<category><![CDATA[ESC]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14095</guid>
		<description><![CDATA[Yesterday, AstraZeneca Plc (AZN) announced that Crestor, its cholesterol-lowering drug (statin) reduced the risk of heart attacks, strokes, artery-clearing procedures and death in elderly patients. The results from the JUPITER study (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin), showed that Crestor 20mg reduced major cardiovascular events. The administration of the drug to a sub-set of 5,695 patients aged 70 years or above reduced the risk of cardiovascular events by 39% compared to placebo. The study also revealed that Crestor reduced the risk of heart attack as well as stroke by 45% each in 17,802 patients (the total population of the study). The results were presented at the European Society of Cardiology (ESC) meeting in Barcelona, Spain. Results from the randomized, double-blind, placebo-controlled study ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/01/azn-good-news-for-astrazeneca-on-crestor-its-cholesterol-lowering-drug/14095/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Announces New Management Structure for Schering-Plough Merger</title>
		<link>http://www.stockbloghub.com/2009/09/01/mrk-merck-announces-new-management-structure-for-schering-plough-merger/14038</link>
		<comments>http://www.stockbloghub.com/2009/09/01/mrk-merck-announces-new-management-structure-for-schering-plough-merger/14038#comments</comments>
		<pubDate>Tue, 01 Sep 2009 16:50:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14038</guid>
		<description><![CDATA[With the merger of Merck (MRK) and Schering-Plough (SGP) scheduled to be completed by the fourth quarter this year, Merck is busy with the necessary groundwork. Yesterday, the company announced the new management structure post merger. The current chairman, president and CEO of Merck, Richard T. Clark, will continue to head the combined company. The merged entity will comprise five main divisions &#8212; Global Human Health, Animal Health, Consumer Healthcare, Research and Manufacturing. Global Human Health, the combined company’s largest segment, will be headed by Kenneth Frazier, who is currently heading that division of Merck. This division will include prescription drugs, biologics and vaccines along with an emerging-markets group. Both the Research and Manufacturing segments will be headed by the respective current heads at Merck. The Animal Health and Consumer ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/01/mrk-merck-announces-new-management-structure-for-schering-plough-merger/14038/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SGP) Euro Review for Schering Drugs</title>
		<link>http://www.stockbloghub.com/2009/08/27/sgp-euro-review-for-schering-drugs/13712</link>
		<comments>http://www.stockbloghub.com/2009/08/27/sgp-euro-review-for-schering-drugs/13712#comments</comments>
		<pubDate>Fri, 28 Aug 2009 00:12:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13712</guid>
		<description><![CDATA[Yesterday, Schering-Plough Corp. (SGP) revealed that the European Medicines Agency (EMA) will review its candidate for maintenance treatment of asthma in patients 12 years and above and an oral contraceptive for marketing in Europe. While the fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years and above is currently under review by the U.S. Food and Drug Administration (FDA), the filing for FDA approval of the contraceptive is expected in 2010. The oral contraceptive is a combination of a natural estrogen (which is identical to the estrogen produced by a woman&#8217;s body) and a selective progestin. The drug was licensed from Merck KGaA. Schering is seeking marketing approval in Europe for the combination to prevent pregnancy. The approval of the combination ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/sgp-euro-review-for-schering-drugs/13712/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MAA) European Medicines Agency Accepts Merck&#8217;s Application</title>
		<link>http://www.stockbloghub.com/2009/08/27/maa-european-medicines-agency-accepts-mercks-application/13720</link>
		<comments>http://www.stockbloghub.com/2009/08/27/maa-european-medicines-agency-accepts-mercks-application/13720#comments</comments>
		<pubDate>Thu, 27 Aug 2009 23:56:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[REIT - Residential]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[Mid-America Apartment Communit]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13720</guid>
		<description><![CDATA[We are pleased to hear that the European Medicines Agency (EMEA) has agreed to review the Marketing Authorization Application (MAA) of Merck’s (MRK) vernakalant intravenous (IV). The company is seeking EMEA approval for the drug to address the unmet need for patients suffering from acute atrial fibrillation (AF, abnormal heart rhythms leading to strokes). Along with the IV version, Merck is also developing the oral form of the drug, which is currently in phase II development. In April 2009, Merck entered into a collaboration and licensing agreement with Cardiome Pharma Corp. in order to develop and commercialize vernakalant. While Merck retains the exclusive global rights to the oral formulation of vernakalant, its affiliate, MSD Switzerland GmbH gets the rights to the IV formulation outside the US, Canada and Mexico. Atrial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/maa-european-medicines-agency-accepts-mercks-application/13720/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LGND) Ligand Pharmaceuticals to Buy Neurogen</title>
		<link>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310</link>
		<comments>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310#comments</comments>
		<pubDate>Tue, 25 Aug 2009 21:36:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LGND]]></category>
		<category><![CDATA[Ligand Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Neurogen Corporation]]></category>
		<category><![CDATA[NRGN]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13310</guid>
		<description><![CDATA[Yesterday, Ligand Pharmaceuticals Inc. (LGND) announced it has agreed to purchase Neurogen (NRGN) for $11 million in stock as well as certain future cash payments based on licensing deals, real estate sales and other milestones. The deal, which is expected to close by the fourth quarter of this year, has been approved by both company boards. Additionally, Neurogen shareholders, representing approximately 33% of outstanding shares, have already given their nod in favor of the deal. The terms of the deal require Ligand to issue about 4 million new shares to Neurogen shareholders, which is equivalent to a purchase price of 16 cents per common share of Neurogen. Neurogen stockholders would hold 3% of the combined company. The transaction will give Ligand shareholders access to Neurogen&#8217;s partnership with Merck &#38; Co., ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/25/lgnd-ligand-pharmaceuticals-to-buy-neurogen/13310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XOM) Stock Market News for August 24, 2009</title>
		<link>http://www.stockbloghub.com/2009/08/24/xom-stock-market-news-for-august-24-2009/13192</link>
		<comments>http://www.stockbloghub.com/2009/08/24/xom-stock-market-news-for-august-24-2009/13192#comments</comments>
		<pubDate>Mon, 24 Aug 2009 21:26:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Major Integrated Oil & Gas]]></category>
		<category><![CDATA[AIG]]></category>
		<category><![CDATA[American International Group,]]></category>
		<category><![CDATA[Chevron Corp.]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Exxon Mobil Corp.]]></category>
		<category><![CDATA[GameStop Corp.]]></category>
		<category><![CDATA[GME]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13192</guid>
		<description><![CDATA[Federal Reserve Chairman Ben Bernanke’s encouraging words about the economy and a jump in existing home sales sent US stock surging to their highest level this year and brightened hopes that an economic recovery is imminent.  Treasuries tumbled and corresponding yields rose sharply higher as investors turned away from the safety of government debt.  Gains were broad based with 29 of the 30 Dow Jones industrial average components recording gains.  Crude oil prices climbed on the back of economic recovery hopes, hitting a 10-month high of $73.89. US stock futures point to a moderately higher open on Monday.  Dow Jones industrial average futures rose 34, or 0.4%, to 9,523. Standard &#38; Poor&#8217;s 500 index futures rose 3.30, or 0.3%, to 1,028.50, while Nasdaq 100 index futures rose 2.00, or 0.1%, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/24/xom-stock-market-news-for-august-24-2009/13192/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) Glaxo&#8217;s Vaccine Portfolio Expanded</title>
		<link>http://www.stockbloghub.com/2009/08/20/gsk-glaxos-vaccine-portfolio-expanded/12993</link>
		<comments>http://www.stockbloghub.com/2009/08/20/gsk-glaxos-vaccine-portfolio-expanded/12993#comments</comments>
		<pubDate>Fri, 21 Aug 2009 03:30:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12993</guid>
		<description><![CDATA[Yesterday, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline’s (GSK) Hiberix, a Haemophilus influenzae Type b (Hib) vaccine. The vaccine has been approved as a booster dose for children in the age group of 15 months to 4 years. FDA approval was based on safety and efficacy data obtained from 7 clinical studies conducted in Europe, Latin America and Canada involving more than 1,000 children. Hiberix was approved under the FDA&#8217;s accelerated approval pathway, mainly due to a nationwide shortage of Hib vaccines since December 2007. Merck &#38; Co., Inc. (MRK) voluntary recalled and subsequently suspended production of 2 Hib vaccines, PedvaxHIB and COMVAX, licensed in the United States. Following the shortage in Hib vaccines, the U.S. Centers for Disease Control and Prevention temporarily postponed the Hib vaccine booster ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/gsk-glaxos-vaccine-portfolio-expanded/12993/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck received a favorable ruling in a major patent-infringement suit</title>
		<link>http://www.stockbloghub.com/2009/08/20/mrk-merck-received-a-favorable-ruling-in-a-major-patent-infringement-suit/12906</link>
		<comments>http://www.stockbloghub.com/2009/08/20/mrk-merck-received-a-favorable-ruling-in-a-major-patent-infringement-suit/12906#comments</comments>
		<pubDate>Thu, 20 Aug 2009 19:00:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12906</guid>
		<description><![CDATA[Merck (MRK) received a favorable ruling in a major patent-infringement suit yesterday against the largest generic player, Teva Pharmaceuticals (TEVA), on its top-selling drug Singulair. Teva was seeking the Food and Drug Administration’s (FDA) approval for selling a generic version of the drug for asthma and allergic rhinitis. The litigation has been continuing since Merck sued Teva in February 2007. During the second quarter of 2009, Singulair recorded worldwide sales of $1.3 billion, up 16% from the year-ago period. The drug had total sales of $4.3 billion in fiscal 2008, accounting for about 18% of Merck’s total revenue. Defending Singulair’s patent was thus quite crucial for Merck. We believe this is a major win for Merck as an unfavorable ruling would have hurt its top-line badly. The court not only ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/mrk-merck-received-a-favorable-ruling-in-a-major-patent-infringement-suit/12906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) Cornerstone Falls Far Short of Expectations</title>
		<link>http://www.stockbloghub.com/2009/08/20/azn-cornerstone-falls-far-short-of-expectations/12927</link>
		<comments>http://www.stockbloghub.com/2009/08/20/azn-cornerstone-falls-far-short-of-expectations/12927#comments</comments>
		<pubDate>Thu, 20 Aug 2009 18:22:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12927</guid>
		<description><![CDATA[Last week, Cornerstone Therapeutics Inc. (CRTX) reported second quarter earnings of 13 cents per share, which was well below the Zacks Consensus Estimate of 33 cents. Net revenues for the quarter came in at $25 million, which reflected a 78% increase over the prior-year quarter. The company reported earnings of 31 cents per share in the previous year quarter. Operating expenses increased significantly in the quarter primarily due to increases in the workforce &#8212; an increase in legal and accounting costs, costs associated with the Chiesi transaction, FDA regulatory-related fees, product liability, insurance-related costs, new product launches and royalties on increased product sales. As a reminder, Cornerstone Therapeutics Inc. was established through the merger of Critical Therapeutics with Cornerstone Biopharma Holdings Inc. in the fourth quarter of 2008. The financial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/azn-cornerstone-falls-far-short-of-expectations/12927/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HPQ) Stock Market News for August 20, 2009 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2009/08/20/hpq-stock-market-news-for-august-20-2009-market-news/12863</link>
		<comments>http://www.stockbloghub.com/2009/08/20/hpq-stock-market-news-for-august-20-2009-market-news/12863#comments</comments>
		<pubDate>Thu, 20 Aug 2009 17:34:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Computer Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Barnes & Noble]]></category>
		<category><![CDATA[BJ]]></category>
		<category><![CDATA[BJ's Wholesale Club Inc.]]></category>
		<category><![CDATA[BKS]]></category>
		<category><![CDATA[Chevron Corp.]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DE]]></category>
		<category><![CDATA[Deere & Company]]></category>
		<category><![CDATA[Exxon Mobil Corp.]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold]]></category>
		<category><![CDATA[GameStop Corp.]]></category>
		<category><![CDATA[Gap Inc.]]></category>
		<category><![CDATA[GME]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPS]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HJ Heinz Company]]></category>
		<category><![CDATA[HNZ]]></category>
		<category><![CDATA[Hormel Foods Corp.]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[HRL]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Co]]></category>
		<category><![CDATA[Limited Brands Inc.]]></category>
		<category><![CDATA[LTD]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PETM]]></category>
		<category><![CDATA[Petsmart Inc.]]></category>
		<category><![CDATA[Ross Stores Inc.]]></category>
		<category><![CDATA[ROST]]></category>
		<category><![CDATA[Sears Holdings Corporation]]></category>
		<category><![CDATA[SHLD]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12863</guid>
		<description><![CDATA[A sharp rebound in Chinese shares helped erase yesterday’s slump and sent Asian stocks sharply higher Thursday, a day after Shanghai’s big fall ignited fears of a Chinese stock collapse and triggered a selling spree around the world.  Asian markets also drew comfort from an overnight recovery on Wall Street after a surprise drop in U.S. crude stockpiles lifted hopes for an economic recovery and sent investors back on the buying table. Shanghai&#8217;s main index jumped 126 points, or 4.5%, to 2,911.58, while Japan&#8217;s Nikkei 225 stock average climbed 179.41 points, or 1.8%, to 10,383.41.  Hong Kong&#8217;s Hang Seng rose 374.63, or 2%, to 20,336.36.  South Korea’s Kospi advanced 2% to 1,576.39. Stock futures pointed to a higher open on Wall Street Thursday.  Dow Jones industrial average futures rose 24, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/hpq-stock-market-news-for-august-20-2009-market-news/12863/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) Pharma Majors to Gain from India</title>
		<link>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677</link>
		<comments>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677#comments</comments>
		<pubDate>Wed, 19 Aug 2009 22:21:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12677</guid>
		<description><![CDATA[All major pharmaceutical companies that have operations in India are likely to benefit from the latest decision made by the Commerce Ministry in that country. The ministry accepted the Mashelkar committee’s report, according to which India will continue to allow patents on incremental innovations if the enhancements are beneficial to patients. The decision was taken amidst severe protests from generic players and health activists who fear this will not allow cheaper generic drugs to enter the market. On the basis of 2008 sales figures, the Indian pharmaceutical market ranks 13th in the world, with sales of $7.7bn last year (an increase of 4% over 2007). The rapidly growing middle income group with higher disposable income makes it an attractive place for major pharma companies. The pharmaceutical market is expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/gsk-pharma-majors-to-gain-from-india/12677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Lilly Discontinues Arzoxifene Trials</title>
		<link>http://www.stockbloghub.com/2009/08/19/lly-lilly-discontinues-arzoxifene-trials/12728</link>
		<comments>http://www.stockbloghub.com/2009/08/19/lly-lilly-discontinues-arzoxifene-trials/12728#comments</comments>
		<pubDate>Wed, 19 Aug 2009 21:43:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12728</guid>
		<description><![CDATA[Yesterday, Eli Lilly and Company (LLY) announced that it will not seek approval from the U.S. Food and Drug Administration (FDA) for its phase III pipeline candidate, arzoxifene, which is being developed for the prevention and treatment of osteoporosis in postmenopausal women and the reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis or low bone mass. The company released initial results from a pivotal, five-year, phase III study (GJAD GENERATIONS) which showed that arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women. However, the study failed to meet its main secondary efficacy endpoints. The candidate failed to show a statistically significant difference in endpoints like non-vertebral fractures, clinical vertebral fractures, cardiovascular events and cognitive function, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/lly-lilly-discontinues-arzoxifene-trials/12728/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Mixed Ruling for Amgen&#8217;s Drug</title>
		<link>http://www.stockbloghub.com/2009/08/14/amgn-mixed-ruling-for-amgens-drug/12573</link>
		<comments>http://www.stockbloghub.com/2009/08/14/amgn-mixed-ruling-for-amgens-drug/12573#comments</comments>
		<pubDate>Fri, 14 Aug 2009 23:30:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12573</guid>
		<description><![CDATA[Yesterday, the U.S. Food and Drug Administration&#8217;s (FDA) advisory panel ruled in favor of Amgen’s (AMGN) osteoporosis drug denosumab (proposed trade name: Prolia), but with certain exceptions. While the advisory panel unanimously gave its stamp of approval to the injectable drug for prevention of bone fractures in women with postmenopausal osteoporosis, it stated that the drug should only be used by patients facing the highest risk of fractures. The ruling was based on safety and efficacy data from 30 studies of the drug involving more than 12,000 patients. However, the panel did not approve use of the drug in the prevention and treatment of bone loss in women with breast cancer undergoing hormone ablation. It demanded additional data to ensure that denosumab would not hasten tumor growth in such patients, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/14/amgn-mixed-ruling-for-amgens-drug/12573/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SGP) Schering-Plough Settles Lawsuits &#8211; Analyst Blog</title>
		<link>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445</link>
		<comments>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445#comments</comments>
		<pubDate>Thu, 13 Aug 2009 00:22:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Caraco Pharmaceutical Laborato]]></category>
		<category><![CDATA[CPD]]></category>
		<category><![CDATA[Dr. Reddys Laboratories]]></category>
		<category><![CDATA[GeoPharma Inc.]]></category>
		<category><![CDATA[GORX]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12445</guid>
		<description><![CDATA[Yesterday, Schering-Plough Corp. (SGP) said it has signed an agreement with Orchid Chemicals &#38; Pharmaceuticals Ltd. and Orgenus Pharma Inc., which sought to make generic versions of its allergy drug Clarinex. This signals the end of all pending litigations that Schering filed against several generic drug manufacturing companies in the US District Court of New Jersey since 2006. These companies wanted to market solid oral doses of the drug, desloratadine, in the U.S. as generic brands before the expiration of certain Schering patents. Pursuant to the agreement, Orchid received rights to launch a generic version of the Clarinex brand Reditabs in the U.S. on Jan. 1, 2012 and Clarinex brand 5 milligram tablets on July 1 of that year. Schering holds various patents related to Clarinex till 2022. Schering has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/12/sgp-schering-plough-settles-lawsuits-analyst-blog/12445/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) Glaxo Expands Vaccine Portfolio &#8211; will buy Nabi’s PentaStaph vaccine</title>
		<link>http://www.stockbloghub.com/2009/08/10/gsk-glaxo-expands-vaccine-portfolio-will-buy-nabi%e2%80%99s-pentastaph-vaccine/12263</link>
		<comments>http://www.stockbloghub.com/2009/08/10/gsk-glaxo-expands-vaccine-portfolio-will-buy-nabi%e2%80%99s-pentastaph-vaccine/12263#comments</comments>
		<pubDate>Tue, 11 Aug 2009 02:16:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NABI]]></category>
		<category><![CDATA[Nabi Biopharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12263</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) recently entered an agreement with Nabi Biopharmaceuticals (NABI) to bring a new pipeline candidate into its vaccine portfolio. Glaxo will buy Nabi’s PentaStaph vaccine, which is being developed to fight hospital-acquired staph infection. Staph infections are caused by a drug-resistant strain of bacteria often found in hospitals. PentaStaph is being tested against three different strains of staph and two other antigens. The deal is valued at $46 million, of which $20 million will be paid immediately. The remaining $26 million will be paid after achievement of four key milestones. The deal is scheduled to close by year-end and Nabi expects to achieve the four milestone payments within 18 months. GlaxoSmithKline has a strong presence in the vaccine market. The company’s acquisition of ID Biomedical in 2005 helped Glaxo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/10/gsk-glaxo-expands-vaccine-portfolio-will-buy-nabi%e2%80%99s-pentastaph-vaccine/12263/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAT) Earnings Optimism Hides Ugly Truth</title>
		<link>http://www.stockbloghub.com/2009/07/21/cat-earnings-optimism-hides-ugly-truth/10965</link>
		<comments>http://www.stockbloghub.com/2009/07/21/cat-earnings-optimism-hides-ugly-truth/10965#comments</comments>
		<pubDate>Tue, 21 Jul 2009 20:04:17 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Farm & Construction Machinery]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[BlackRock]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Coca-Cola Company]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=10965</guid>
		<description><![CDATA[by The Investment U Research Team The mood seems to have soured on Wall Street since its bounce early this morning. And if you peer beneath the headlines, you can see why. The big news has been Caterpillar’s (NYSE: CAT) earnings, which tripled analyst’s expectations. But as we look deeper, we find that CAT’s earnings are well below last year’s figures. Merck (NYSE: MRK) announced that earnings dropped less than expected. Again, note revenue still dropped 2%. State Street (NYSE: STT) reported a loss of almost $3.3 billion as it writes down asset values. Coca-Cola (NYSE: KO) also announced lower earnings, citing stronger dollar. On the surface, these earnings reports sound good, but they hide the ugly truth. And the list goes on, from BlackRock (NYSE: BLK), Freeport-McMoRan (NYSE: FCX) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/21/cat-earnings-optimism-hides-ugly-truth/10965/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072</link>
		<comments>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072#comments</comments>
		<pubDate>Tue, 09 Jun 2009 18:48:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8072</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/09/pfe-pharmaceuticals-biotech-zacks-analyst-interviews/8072/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharmaceuticals &amp; Biotech &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043</link>
		<comments>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043#comments</comments>
		<pubDate>Mon, 08 Jun 2009 22:05:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Incorporated]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corp. plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=8043</guid>
		<description><![CDATA[The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x Incorporatedluding: Pfizer (PFE), 7.5x, Eli Lilly (LLY), 8.1x, Merck (MRK), 8.3x, Sanofi (SNY), 7.5x, AstraZeneca (AZN), 7.6x and GlaxoSmithKline (GSK), 9.3x based on our fiscal 2009 estimates. Attractive valuations, along with big dividend yields, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/06/08/wye-pharmaceuticals-biotech-industry-outlook/8043/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Drug Companies: A Powerhouse of Profits</title>
		<link>http://www.stockbloghub.com/2009/05/09/mrk-drug-companies-a-powerhouse-of-profits/6849</link>
		<comments>http://www.stockbloghub.com/2009/05/09/mrk-drug-companies-a-powerhouse-of-profits/6849#comments</comments>
		<pubDate>Sat, 09 May 2009 23:36:21 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=6849</guid>
		<description><![CDATA[by The Investment U Research Team A couple of interesting news items came out in the past few days. One, a research report showing how expensive treatment is for childhood mental issues. It also showed that in 2006 over 13 million children were treated for asthma at a cost of $8 billion. The other a study that finds more Americans than ever are taking some sort of prescription for mental illness – 73% more than in 1996. What’s interesting, apart from the fact that we seem to be overmedicating as a society, is that the numbers of patients and the costs of treatments spell hundreds of billions in profits for healthcare and drug makers. Taking a look at the eleven largest, we find that their market caps total almost $900 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/05/09/mrk-drug-companies-a-powerhouse-of-profits/6849/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(IBM) Stock Market News for April 20, 2009 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2009/04/20/ibm-stock-market-news-for-april-20-2009-market-news/5769</link>
		<comments>http://www.stockbloghub.com/2009/04/20/ibm-stock-market-news-for-april-20-2009-market-news/5769#comments</comments>
		<pubDate>Mon, 20 Apr 2009 20:06:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Computer Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Coca-Cola Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[General Motors Corporation]]></category>
		<category><![CDATA[GM]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machine]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Co]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corp.]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[Pepsico Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5769</guid>
		<description><![CDATA[US stocks ended another week on a winning note as earnings reports, although not great by normal standards, and a consumer sentiment survey indicated the economy and financial markets are showing signs of stabilization.  The Dow Jones industrial average closed the week up 47.95, or 0.6%, at 8,131.33. The Standard &#38; Poor&#8217;s 500 index rose 13.04, or 1.5%, to 869.60.  The tech-heavy Nasdaq rose 20.53, or 1.2%, to 1,673.07.  The broad-based S&#38;P 500, which recorded its steepest six-week gain since 1938, is now up 29% since hitting its 12-year nadir on March 9. As risk appetite grew treasuries declined, taking the yield on the 2-year to 0.981% and the 10-year to 2.953% as prices fell 4/32 and 30/32, respectively on Friday. The Vix, CBOE&#8217;s volatility index, declined 2.59 points over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/20/ibm-stock-market-news-for-april-20-2009-market-news/5769/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WYE) Biotech Industry &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310</link>
		<comments>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310#comments</comments>
		<pubDate>Fri, 13 Mar 2009 22:00:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMAG]]></category>
		<category><![CDATA[AMAG Pharmaceuticals]]></category>
		<category><![CDATA[Celera Corporation]]></category>
		<category><![CDATA[CRA]]></category>
		<category><![CDATA[DCGN]]></category>
		<category><![CDATA[deCODE genetics Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[SRDX]]></category>
		<category><![CDATA[SurModics Inc.]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4310</guid>
		<description><![CDATA[OVERVIEW The financial market and the economic landscape in the U.S. have not changed much since the beginning of the year. And we believe the status quo will last for a while at least in 2009. Large biotech companies are doing OK since they have strong balance sheets to weather the current market turmoil and can generate revenue from product sales. Investors in large biotechnology companies worth more than $1 billion have preserved much of their wealth. Smaller biotech companies, particularly those still in development stage, meanwhile, are under severe strain as the global economic slump cuts into sales and their ability to raise fresh cash to fund research. As we expected, the M&#38;A spree has continued in the first three months of this year. Following the acquisition of Wyeth ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/13/wye-biotech-industry-industry-outlook/4310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

